Subscribe for email alerts
Donate to Science & Enterprise
|
By Alan, on January 23rd, 2015% Exosome illustration (NIH.gov)
23 January 2015. A new challenge on InnoCentive is asking for systematic techniques for using exosomes, tiny components that cells secrete for specialized functions, as vehicles to deliver drugs. The challenge has a purse of $30,000 and a submission deadline of 17 February 2015.
InnoCentive in Waltham, Massachusetts conducts open-innovation, . . . → Read More: Challenge Seeks Exosome Drug Delivery Technologies
By Alan, on January 23rd, 2015% Microfluidics devices — labs on chips or disks — are among the technologies with commercial use developed at national labs. (Jeff McMillan, Sandia National Lab.)
23 January 2015. Lawrence Livermore and Sandia National Laboratories are partnering with the Graduate School of Management at University of California in Davis to train scientists in entrepreneurial skills . . . → Read More: UC-Davis, National Labs to Train Science Entrepreneurs
By Alan, on January 22nd, 2015% AliveECG app on an Android device (AliveCor Inc.)
22 January 2015. An algorithm analyzing signals to detect atrial fibrillation from a heart monitor built into mobile devices received regulatory approval in Europe. AliveCor, a developer of heart monitoring systems for mobile devices, says the company received the Conformité Européene or CE mark for . . . → Read More: Mobile Heart Monitor Algorithm Approved in Europe
By Alan, on January 22nd, 2015% T-cell (NIAID/NIH)
22 January 2015. Autolus Ltd., a new enterprise developing engineered immune-system cells for treating cancer, is being formed in London, with £30 million ($45.4 million) in early financing. The company is founded and commercializing research by Martin Pule, a hematologist at University College London.
Pule, who serves as Autolus’s chief scientist, . . . → Read More: Cancer Therapy Spin-Off Formed with $45M Funding
By Alan, on January 21st, 2015% Interleukin-17 illustration (Boghog/Wikimedia Commons)
21 January 2015. U.S. Food and Drug Administration approved the biologic drug secukinumab for adults with moderate to severe plaque psoriasis, a common skin disorder. Secukinumab, an antibody designed specifically to address the condition, is marketed by the pharmaceutical company Novartis under the brand name Cosentyx.
Plaque psoriasis is the . . . → Read More: FDA Approves Novartis Psoriasis Drug
By Alan, on January 21st, 2015% (M4D Group/Flickr)
21 January 2015. Zymeworks Inc., a biotechnology company in Vancouver, Canada and pharmaceutical maker Celgene Inc. are developing biologic therapies using Zymeworks’ antibody technology. The deal makes Zymeworks eligible for up to $164 million from Celgene for each candidate developed under the partnership, as well as an unspecified initial payment and . . . → Read More: Zymeworks, Celgene to Develop Double-Binding Antibodies
By Alan, on January 20th, 2015% Annagh Haven is a thoroughbred race horse who had her jaw repaired with a technology developed by a spin-off enterprise in Ireland. With Annagh Haven, l-r, is Ireland’s Minister for Jobs, Enterprise, and Innovation Damien English, Fergal O’Brien in whose lab the technology was developed, and Laurence Mulvany, owner of Annagh Haven.
20 . . . → Read More: University Spin-Off Develops Bone Repair Technology
By Alan, on January 20th, 2015% Jean Bennett (University of Pennsylvania)
20 January 2015. An early-stage clinical trial is underway testing a gene-repair therapy for choroideremia, a rare progressive genetic eye disorder that leads to blindness. The trial, conducted at Children’s Hospital of Philadelphia began enrolling its first patients, according to Spark Therapeutics, also of Philadelphia, the biotechnology company . . . → Read More: Trial Testing Gene Therapy for Rare Eye Disorder
By Alan, on January 19th, 2015% (FitBit Inc.)
19 January 2015. The U.S. Food and Drug Administration on Friday released draft guidance defining low-risk general wellness devices that the agency intends to exclude from regulatory oversight. The 8-page document, published on the FDA Web site, will be open for comment for 90 days beginning tomorrow.
FDA says it prepared . . . → Read More: FDA Issues Draft Wellness Device Guidance
By Alan, on January 16th, 2015% Alpha-synuclein illustration (Michael J. Fox Foundation)
16 January 2015. UCB, a biopharmaceutical company in Brussels, is licensing an experimental drug to treat Parkinson’s disease developed by Neuropore Therapies Inc., a biotechnology company in San Diego. The agreement gives UCB a worldwide license for the compound and is expected to pay Neuropore as much . . . → Read More: Neuropore, UCB Partner on Parkinson’s Drugs
|
Welcome to Science & Enterprise Science and Enterprise is an online news service begun in 2010, created for researchers and business people interested in taking scientific knowledge to the marketplace.
On the site’s posts published six days a week, you find research discoveries destined to become new products and services, as well as news about finance, intellectual property, regulations, and employment.
|
You must be logged in to post a comment.